Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153]

The authors regret that the affiliations mentioned for the authors are incorrect and that the name of the senior author, Hang Quach, was omitted in the published article. Please find below the correct author list and affiliations. Philippe Moreau1, Gurdeep Parmar2, Miles Prince3, Enrique M. Ocio4, Chatchada Karanes5, Sumit Madan6, Albert Oriol7, Pierre Bories8, Michel Delforge9, Nashat Gabrail10, Dorothee Semiond11, Nan Jia11, Sandrine Macé12, Florence Suzan12, Helgi van de Velde11, Hang Quach13 1University Hospital of Nantes, Nantes, France 2Illawarra Cancer Care Centre, Wollongong, NSW, Australia 3Epworth Healthcare and University of Melbourne, Melbourne, Vic, Australia 4University of Cantabria, Santander, Spain 5City of Hope National Medical Center, Duarte, CA, USA 6Banner MD Anderson Cancer Center, Gilbert, AZ, USA 7Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain 8Réseau Régional de Cancérologie Onco-Occitanie, Toulouse, France 9University Hospitals Leuven, Leuven, Belgium 10Gabrail Cancer Center, Canton, OH, USA 11Sanofi, Cambridge, MA, USA 12Sanofi, Vitry-sur-Seine, France 13St Vincent's Hospital, University of Melbourne, VIC, Australia The authors would like to apologise for any inconvenience caused.